Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Allopurinol Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

NCT02888054
View directory record Official record
Conditions
Healthy
Interventions
lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels

NCT00987415
View directory record Official record
Conditions
Heart Failure, Elevated Serum Uric Acid
Interventions
allopurinol, sugar pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Combining Lesinurad With Allopurinol in Inadequate Responders

NCT01510158
View directory record Official record
Conditions
Gout
Interventions
Lesinurad, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
165
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 139 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 3 Interventional

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

NCT07089888
View directory record Official record
Conditions
Tophaceous Gout
Interventions
Allopurinol, Dotinurad
Drug
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
94
States / cities
Birmingham, Alabama • Foley, Alabama • Gilbert, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Gender Differences in the Metabolic Effects of Uric Acid

NCT03076684
View directory record Official record
Conditions
Hyperuricemia
Interventions
low-fructose diet, Allopurinol
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

NCT02991898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
Interventions
Infusion of Treg
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 3 Interventional

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

NCT05586971
View directory record Official record
Conditions
Gout, Hyperuricemia, Gout Flare, Tophi
Interventions
Tigulixostat, Allopurinol, Placebo
Drug
Lead sponsor
LG Chem
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
124
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Allopurinol Outcome Study

NCT01391325
View directory record Official record
Conditions
Gout
Interventions
Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
127
States / cities
Birmingham, Alabama • Bringham, Alabama • Calera, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia

NCT06056570
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
dotinurad, dotinurad + allopurinol, allopurinol
Drug
Lead sponsor
Urica Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Clearwater, Florida • Miami Lakes, Florida • Mesquite, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 4 Interventional

Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout

NCT01310673
View directory record Official record
Conditions
Gout, Gout Acute
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

Uric Acid Reduction as a Novel Treatment for Pediatric Chronic Kidney Disease

NCT03865407
View directory record Official record
Conditions
Hyperuricemia, Chronic Kidney Diseases
Interventions
Allopurinol
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 20 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 3 Interventional

Lesinurad and Allopurinol Combination Extension Study in Gout

NCT01808131
View directory record Official record
Conditions
Gout
Interventions
Lesinurad
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Pinson, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 3, 2026, 2:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

NCT04746989
View directory record Official record
Conditions
Gout
Interventions
Probenecid, Allopurinol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
294,878 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

NCT05536349
View directory record Official record
Conditions
Leukemia
Interventions
Pirtobrutinib, Obinutuzumab, Venetoclax, Valacyclovir, Allopurinol
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer

NCT00652899
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions
Allopurinol, Cyclophosphamide, Fludarabine phosphate, total-body irradiation, Allogeneic natural killer cells, Aldesleukin
Biological · Drug · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of PK and Safety of D-0120 and Allopurinol

NCT05360628
View directory record Official record
Conditions
Healthy
Interventions
D-0120 in combination with Allopurinol
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Not applicable Interventional Results available

The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study

NCT01701622
View directory record Official record
Conditions
Blood Pressure, Gout
Interventions
febuxostat
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 3, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional Results available

Allopurinol Maintenance Study for Bipolar Disorder

NCT00732251
View directory record Official record
Conditions
Bipolar Disorder, Mania, Mixed Mania
Interventions
Allopurinol
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Sep 3, 2026, 2:16 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy

NCT00281255
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiomyopathy, Dilated, Heart Diseases, Heart Failure, Congestive
Interventions
Allopurinol, Dobutamine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 3, 2026, 2:16 PM EDT
Recruiting Phase 4 Interventional

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

NCT04875702
View directory record Official record
Conditions
Gout
Interventions
Allopurinol, Naproxen 250 MG, Colchicine 0.6 mg, Colchicine 1.2 mg, Naproxen 500 Mg, Prednisone 40 mg
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
South Birmingham, Alabama • Santa Monica, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Febuxostat in Participants With Gout

NCT00430248
View directory record Official record
Conditions
Gout
Interventions
Febuxostat, Allopurinol
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
258
States / cities
Birmingham, Alabama • Hoover, Alabama • Hueytown, Alabama + 255 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 3, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Effectiveness of Rilonacept for the Prevention of Gout Flares

NCT00610363
View directory record Official record
Conditions
Gout
Interventions
Rilonacept, Placebo (for Rilonacept)
Biological · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
San Diego, California • Santa Maria, California • Whittier, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 3, 2026, 2:16 PM EDT